February 10, 2022 GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights February 7, 2022 GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10 December 20, 2021 GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences December 13, 2021 GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test November 30, 2021 GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study November 11, 2021 GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights November 1, 2021 GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11 November 1, 2021 GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing October 13, 2021 GBS Inc. Announces its Pre-Submission package is with the FDA September 7, 2021 GBS Inc. to Present at Upcoming September Virtual Investor Conferences
February 10, 2022 GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
February 7, 2022 GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10
December 13, 2021 GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test
November 30, 2021 GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study
November 11, 2021 GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
November 1, 2021 GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11
November 1, 2021 GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
